Core Viewpoint - Hendi Pharmaceutical Co., Ltd. announced a share reduction plan involving three shareholders, aiming to reduce a total of up to 9.744 million shares, representing 2.33% of the company's total share capital [1][2]. Share Reduction Plan Details - The share reduction plan involves three shareholders: Jingmen Ningkang Enterprise Management Center (Limited Partnership), Jingmen Beikang Enterprise Management Center (Limited Partnership), and Lei Xiaoyan, all citing "personal financial planning" as the reason for the reduction [2]. - The specific reduction plans are as follows: - Ningkang Enterprise plans to reduce up to 4.176 million shares (1% of total shares) from December 4, 2025, to March 3, 2026 [2]. - Beikang Enterprise plans to reduce up to 1.392 million shares (0.33% of total shares) during the same period [2]. - Lei Xiaoyan plans to reduce up to 4.176 million shares (1% of total shares) from November 18, 2025, to February 17, 2026 [2]. Shareholder Basic Information - The shareholdings of the three shareholders are as follows: - Ningkang Enterprise holds 23.49 million shares (5.63% of total shares) [3]. - Beikang Enterprise holds 7.83 million shares (1.88% of total shares) [3]. - Lei Xiaoyan holds 15.66 million shares (3.75% of total shares) [3]. Compliance and Commitment Fulfillment - The share reduction plan complies with previous commitments made by the shareholders, who had locked their shares for 36 months post-IPO, with an automatic extension if the stock price fell below the IPO price within six months [3][4]. - As of the announcement date, all three shareholders have adhered to their share lock-up and reduction intentions without any violations [4].
湖北亨迪药业三股东拟合计减持不超974.4万股 占总股本2.33%